The study, published in Nature Communications, was supported by the minister for nanotechnology, Dr Padraig McGarry, extending the facility at Trinity College Dublin to additional HSE sites, adding the full range of research studies to be conducted, to include its next phase clinical trials.
To address these issues, the team at Trinity carried out in-depth experiments on mice that did not tolerate infection with FAP (breast carcinoma) and FMEL (geriatrics-associated lymphoma), cultures of neurons from rats infected with FAP, mice that received a mixture of tafam abuvacain and FMEL, and mice that did not receive tafam abuvacain and FMEL enzymes.
Given the younger blood plasma donor population currently on trolleys everywhere (15 to 25 year old), it begs the question is anyone sitting on trolleys anymore?
So, given that we have seen this with little to no research focus in the last few years, we feel confident that clinical studies in the patient group with FAP will yield data that will be useful to new and in-depth clinical studies of those patients who have undergone personalized hormone therapy; this is a very exciting market area for us.”